scholarly journals Active pharmaceutical ingredients in dermatological medicines of Ukrainian pharmaceutical market

2019 ◽  
pp. 9-19
Author(s):  
I. O. Vlasenko ◽  
L. L. Davtian
Keyword(s):  
Diabetic Foot ◽  
Marketing Research ◽  
Pharmaceutical Market ◽  
Active Pharmaceutical Ingredients ◽  
Sources Of Information ◽  
Pharmaceutical Ingredients ◽  
Other Substances ◽  
Future Drug ◽  
Wound Healing Effect ◽  
Trade Names

The problem of the diabetic foot is one of the most serious complications of diabetes mellitus. There is still an active search for medicines (drugs) that could be used in the complex treatment of trophic lesions in diabetic foot. The period before the development and launch of the drug into the pharmaceutical market need to make marketing research aimed at ensuring that the future drug is competitive. The purpose of the work was to analyze the market of dermatological drugs for the treatment of trophic ulcers in order to determine the marketing opportunities for domestic producers. The research objects were active pharmaceutical ingredients (APIs), which are part of the dermatological registered drugs in Ukraine. Materials for research were official sources of information about drugs registered in Ukraine. Marketing analytical methods were used. To determine the level of tension between manufacturers and the same product, the coefficient of tension. Number of D preparations registered in Ukraine ‒ 452 trade names (January 2018) was established. Medicines wich prodused by Ukraine are slightly higher (55.3%). In groups D01, D03, D06, D07 and D08 the highest number of APIs is determined, which is 25, 36, 33, 29 and 30, respectively. Part API is contained in the drug in combination with other API. In the D01 group, only a small amount of API ‒ 7 is present in combination with other substances, and in group D02 ‒ 6, certain APIs are part of the combined drug. In preparations of D03 4 API are in combination. In group D06, 12 APIs are contained in combination drugs. Most of the established API groups D07 (13) are found in the drug in combination. In the D08 group, part of the API (8) is part of a combined drug. There is a combination of APIs antiseptic or antimicrobial activity, anti-inflammatory effect, local anesthetic and wound healing effect. According to the results of the calculation of the tension indices between the manufacturers of analogues of drugs in group D, the highest competition (Kvi ≥ 0.800) was observed in the groups D01 and D03 (for 4 drugs with Kvi ≥ 0.800), D06 (3 drugs), D07 (8 drugs), D08 (7 drugs). An analysis of the competitiveness of analogue manufacturers has shown that Ukrainian manufacturers are not sufficiently competing in the production of modern analogues of dermatological drugs.

scholarly journals Drugs, Active Ingredients and Diseases Database in Spanish. Augmenting the Resources for Analyses on Drug–Illness Interactions

Data ◽  
2021 ◽  
Vol 6 (1) ◽  
pp. 3
Author(s):  
Irene López-Rodríguez ◽  
César F. Reyes-Manzano ◽  
Israel Reyes-Ramírez ◽  
Tania J. Contreras-Uribe ◽  
Lev Guzmán-Vargas
Keyword(s):  
Side Effects ◽  
Near Field ◽  
Quantitative Information ◽  
Active Pharmaceutical Ingredients ◽  
Sources Of Information ◽  
Active Ingredients ◽  
Field Exposure ◽  
Essential Information ◽  
Pharmaceutical Ingredients ◽  
Active Substances

Quantitative and qualitative data on active-ingredient drug composition are essential information for characterizing near-field exposure of consumers to product-related chemicals, among other things. Equally as important is the characterization of the relationship between one or many active ingredients in terms of the diseases they are prescribed for. Such evaluations, however, require quantitative information at different anatomical levels. To complement the available sources of information on active substances and diseases, we have designed a database with enough versatility to potentially be used in a variety of analyzes. By using information provided by a well-established online pharmacological dictionary, we present a database with 11 tables which are easy to access and manipulate. Specifically, we present datasets containing the details of 12,827 marketed drug products, 40,164 diseases, 6231 active pharmaceutical ingredients and 4093 side effects. We exemplify the usefulness of our database with three simple visualizations, which confirm the importance of the data for quantifying the complexity in the associations among active substances, diseases and side effects. Although there are databases with detailed information on active substances and diseases, none of them can be found in Spanish. Our work presents an option that contributes substantially to obtaining well classified information in order to evaluate the roles of active pharmaceutical ingredients, diseases and side effects. These datasets also provide information about clinical and pharmacological groupings which may be useful for clinical and academic researchers. The database will be regularly updated and extended with the newly available Virtual Medicinal Products.

scholarly journals The analysis of prolonged-release drugs at the Ukrainian pharmaceutical market

2021 ◽  
Vol 7 (3) ◽  
pp. 64-72
Author(s):  
K. V. Tarapon ◽  
O. V. Tryhubchak
Keyword(s):  
Nervous System ◽  
Classification System ◽  
Marketing Research ◽  
Dosage Forms ◽  
Pharmaceutical Market ◽  
Prolonged Release ◽  
Scientific Analysis ◽  
Inflammatory Drugs ◽  
Trade Names ◽  
Marketing Methods

Aim. To analyze the range of prolonged-release dosage forms at the Ukrainian pharmaceutical market focusing on the pharmacotherapeutic groups that are insufficiently saturated with prolonged-release drugs, in particular to determine the proportion of non-steroidal anti-inflammatory drugs (NSAIDs). Materials and methods. The research was conducted in accordance with the data of the State Registry of Medicines of Ukraine and the АТС classification system. The methods of scientific analysis, in particular methods of grouping and comparison, marketing methods of analysis were applied. Results. The study of the assortment of prolonged-release drugs registered at the Ukrainian pharmaceutical market has been performed. The structure of the assortment by manufacturer, dosage forms, the АТС classification system has been analyzed. As a result of the study, it has been found that 202 trade names of prolonged-release drugs are registered in Ukraine. Most of them (196 names, 84 %) are medicines of foreign manufacturers. Prolonged-release drugs registered in Ukraine are mostly presented in the form of tablets and capsules, but tablets (72.77 %) are the largest part. The analysis of distribution of prolonged-release drugs by the ATC classification groups has shown that a significant number of prolonged-release drugs belongs to group N – Nervous system (80 trade names), and group C – Cardiovascular system (44 trade names). The share of group M – Musculoskeletal system, in particular prolonged-release NSAIDs, is insignificant (9 trade names). Conclusions. The marketing research of the prolonged-release drugs conducted allowed us to characterize the structure of the assortment of the Ukrainian market by pharmacotherapeutic groups, manufacturers and dosage forms. As a result of the research, the current assortment of prolonged-release NSAIDs has been determined.

scholarly journals Pharmaceutical care for patients with diabetes: storage of insulin

2019 ◽  
pp. 21-34
Author(s):  
I. O. Vlasenko ◽  
L. L. Davtian
Keyword(s):  
Diabetes Mellitus ◽  
Pharmaceutical Care ◽  
Joint Ventures ◽  
Marketing Research ◽  
Point Of View ◽  
Sources Of Information ◽  
Foreign Companies ◽  
Patients With Diabetes ◽  
Insulin Activity ◽  
Trade Names

According to statistics, 1.2 million Ukrainians suffer from diabetes, and 201626 people being registered and requiring insulin (PI). In Ukraine, a system of reimbursement is introduced, which provides for the dispatch of PI from pharmacies. Thus, in the process of providing patients with diabetes with insulin, pharmacies play a significant role and, accordingly, provide them with pharmaceutical assistance. Insulin is used to treat both type 1 and type 2 diabetes mellitus. Successful treatment requires confidence that the insulin will work properly. Improper storage can lead to a decrease in insulin activity, which will affect its ability to effectively and predictably control the patient's blood sugar. It is important to provide the patient with correct recommendations for storing insulin when dispensed from the pharmacy. The purpose of the work was to develop practical recommendations for pharmacy workers and patients with diabetes mellitus regarding the storage of PI. The objects of study were electronic and paper sources of information, Instructions for the use of PI. Content analysis and methods of bibliosemantic, marketing, generalization analyzes were applied. Marketing research of PIs whose names are subject to reimbursement on dispensing from pharmacies showed that the number of trade names is 33 names, and taking into account the dosage form – 71. In the bottles are represented 39.4% of drugs, in cartridges – 33.8% and in pre-filled syringes pens – 26.8%. PIs are supplied to the Ukrainian pharmaceutical market by domestic manufacturers, foreign companies and joint ventures. In this case, PIs in bottles are manufactured mainly by domestic manufacturers (16 preparations), cartridge forms – mainly by foreign companies (14 preparations), and pre-filled syringe pens – only by foreign companies (19 preparations). The joint ventures produce only 7 items in vials and cartridges. On the basis of the analysis of documents from different countries, the latest scientific researches and instructions for the use of PI, detailed recommendations have been developed, both for pharmacy workers and for patients with diabetes mellitus, for insulin storage. Attention is drawn to the high risk of exposure to temperature during storage and to the prevention of these risks. The recommendations are developed from the point of view of practical application. Separately formulated tips for storing insulin while traveling. The guidelines are designed to provide pharmaceutical assistance to patients with diabetes at an appropriate level with the release of PI. The issue of proper storage of PIs should be included in the undergraduate and postgraduate training of physicians, nurses, pharmacists and pharmacists. Government agencies should promote a coherent approach to the delivery of medical and pharmaceutical care through the development of national recommendations.

scholarly journals Research of the range of medication for pulmonary hypertension pharmacotherapy in adults in the pharmaceutical market of Ukraine

2021 ◽  
pp. 8-16
Author(s):  
A. V. Kabachna ◽  
I. S. Datsenko ◽  
V. S. Hulpa
Keyword(s):  
Pulmonary Hypertension ◽  
Medical Care ◽  
Import Substitution ◽  
Marketing Research ◽  
Pharmaceutical Market ◽  
Essential Medicines ◽  
Clinical Protocol ◽  
System Review ◽  
Trade Names ◽  
Predominant Effect

Pulmonary hypertension (PH) is a group of rare diseases, malignant in nature, without optimal treatment quickly lead to death. Such patients usually require expensive, continuous and lifelong treatment. Therefore, the study of the assortment structure of drugs used for the treatment of drugs in adults in the domestic market of medicines (drugs) is very relevant. The aim of the study was to analyze the range of drugs for the pharmacotherapy of drugs in the modern pharmaceutical market of Ukraine. The object of the study was information on drugs registered in Ukraine, which are included in the protocol of treatment of patients with PH. In the process of research, system-review, graphic, documentary and marketing research methods were used. The result of the study showed that in the pharmaceutical market of Ukraine there are no drugs based on INN Epoprostenolum, Treprostinil, Beraprostum, Selexipagum, Macitentan, Tadalafilum, Vardenafilum, recommended by the Adapted clinical guidelines for the treatment of adult patients with PH and Unified clinical protocol of emergency, primary, secondary (specialized) and tertiary (hypersensitivity) medical care «Pulmonary hypertension in adults». Simultaneously INN Rivaroxabanum, Apixabanum, Dabigatranum etaxilatum, Iloprostum, Torasemide, Bosentanum, Ambrisentanum, Riociguat are included in the Unified clinical protocol of emergency, primary, secondary (specialized) and tertiary (hypersensitivity) medical care «Pulmonary hypertension in adults» and tertiary (hypersensitivity) Ukraine, however, are not included in the National List of Essential Medicines, which legally limits the possibility of their purchase by health care institutions for budget funds, but only centrally by the Ministry of Health of Ukraine. The structure of drugs for the treatment of PH in adults according to the ATX classification indicates that the largest share have groups С03С – Diuretics – 36.47%, С08С – Selective calcium antagonists with a predominant effect on blood vessels – 32.94%. The import dependence of the pharmaceutical market of medication for PH treatment is relatively high and constitutes about 60% of the number of trade names of medication for PH pharmacotherapy that needs research in the directions of its expansion through import substitution and legislative settlement of questions of improving the accessibility of this medication group.

scholarly journals MARKETING ANALYSIS OF THE ASSORTMENT OF DRUGS FOR THE TREATMENT OF HERPES VIRAL DISEASES AT THE PHARMACEUTICAL MARKET OF UKRAINE

2020 ◽  
Vol 3 ◽  
pp. 70-76
Author(s):  
Lydmila Kienko ◽  
Vita Hrytsenko ◽  
Larysa Iakovlieva ◽  
Larysa Bobrytska
Keyword(s):  
Skin Diseases ◽  
Marketing Research ◽  
Antiviral Effect ◽  
Dosage Forms ◽  
Pharmaceutical Market ◽  
New Drugs ◽  
Viral Diseases ◽  
Sources Of Information ◽  
Marketing Analysis ◽  
Official Sources

Nowadays there is a tendency towards the spread of viral diseases that cause significant complications to human health. Therefore, the question of creating new drugs that have a high antiviral effect is topical. The aim. To study the range of drugs in Ukraine for the treatment of herpes viral diseases. Materials and methods. In the work were used the list of drugs from official sources of information, which were processed by methods of generalization, systematization, graphic, comparative and structural analysis. Results and discussion. The marketing research of drugs for the treatment of herpes viral diseases presented at the pharmaceutical market of Ukraine has been conducted. According to the results it is found that 80 drugs for the treatment of herpes viral diseases of various dosage forms are presented in the domestic market, of which 70 % – tablets; 51 % – medicines produced by the industry of Ukraine; 94 % – are monocomponent preparations. Soft drugs play important role in the treatment of skin diseases because they provide a direct effect of the drugs on the pathogens, eliminate inflammatory phenomena and eliminate or reduce the symptoms of the disease. Soft dosage drugs have practically no contraindications, they can be used at any age, regardless of the presence of comorbidities. Conclusions. Domestic drugs (51 % of the total range) dominate in the market structure. The main part (94 %) consist of monocomponent preparations. The results of the research prove the relevance of the development of new combined soft dosage forms for the treatment of herpes viral diseases, which should be produced by the Ukrainian industry and satisfy the medical and economical needs of patients. The results of the marketing analysis show that it is relevant and promising to create new combined the soft dosage forms for the treatment of herpes viral diseases.

Reversed-Phase High Performance Liquid Chromatographic Analysis of Three First Line Anti-Tuberculosis Drugs

2019 ◽  
Vol 69 (12) ◽  
pp. 3590-3592
Author(s):  
Nela Bibire ◽  
Romeo Iulian Olariu ◽  
Luminita Agoroaei ◽  
Madalina Vieriu ◽  
Alina Diana Panainte ◽  
...  
Keyword(s):  
High Performance ◽  
Biological Fluids ◽  
Gradient Elution ◽  
High Performance Liquid Chromatographic ◽  
Reversed Phase ◽  
Assay Method ◽  
Active Pharmaceutical Ingredients ◽  
First Line ◽  
Pharmaceutical Ingredients ◽  
Liquid Chromatographic

Active pharmaceutical ingredients such as isoniazid, pyrazinamide and rifampicin are among the most important first-line anti-tuberculosis drugs. A simple, rapid and sensitive reversed phase-high performance liquid chromatographic assay method for the simultaneous determination of isoniazid, pyrazinamide and rifampicin has been developed. Separation of the interest compounds was achieved in a 10 min chromatographic run in gradient elution mode on a Zorbax SB-C18 stainless steel column (150 � 4 mm, 5 mm) using a guard column containing the same stationary phase. The gradient elution was carried out with a mobile phase of 10% CH3CN aqueous solution for channel A and 50% CH3CN in pH = 6.8 phosphate buffer (20 mM), to which 1.5 mL triethylamine were added for channel B. Quantification of the analyzed substances was carried out spectrophotometrically at 269 nm. Detection limits of 0.48 mg/L for isoniazid, 0.52 mg/L for pyrazinamide and 0.48 mg/L for rifampicin were established for the developed assay method. The present work showed that the proposed analysis method was advantageous for simple and rapid analysis of the active pharmaceutical ingredients in pharmaceuticals and biological fluids.

scholarly journals Numaswitch: an efficient high-titer expression platform to produce peptides and small proteins

AMB Express ◽  
2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Bach-Ngan Nguyen ◽  
Florian Tieves ◽  
Thomas Rohr ◽  
Hilke Wobst ◽  
Felix S. Schöpf ◽  
...  
Keyword(s):  
Fermentation Broth ◽  
High Titer ◽  
New Technology ◽  
Active Pharmaceutical Ingredients ◽  
Pharmaceutical Ingredients ◽  
Expression Platform ◽  
Small Proteins ◽  
Production Platform ◽  
Β Amyloid ◽  
Cost Efficient

AbstractThe production of peptides as active pharmaceutical ingredients (APIs) by recombinant technologies is of emerging interest. A reliable production platform, however, is still missing due the inherent characteristics of peptides such as proteolytic sensitivity, aggregation and cytotoxicity. We have developed a new technology named Numaswitch solving present limitations. Numaswitch was successfully employed for the production of diverse peptides and small proteins varying in length, physicochemical and functional characteristics, including Teriparatide, Linaclotide, human β-amyloid and Serum amyloid A3. Additionally, the potential of Numaswitch for a cost-efficient commercial production is demonstrated yielding > 2 g Teriparatide per liter fermentation broth in a quality meeting API standard.

scholarly journals Diagnosis of Agglomeration and Crystallinity of Active Pharmaceutical Ingredients in Over the Counter Headache Medication by Electrospray Laser Desorption Ionization Mass Spectrometry Imaging

Molecules ◽  
2021 ◽  
Vol 26 (3) ◽  
pp. 610
Author(s):  
Mariann Inga Van Meter ◽  
Salah M. Khan ◽  
Brynne V. Taulbee-Cotton ◽  
Nathan H. Dimmitt ◽  
Nathan D. Hubbard ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Mass Spectrometry Imaging ◽  
Laser Desorption ◽  
Ionization Mass Spectrometry ◽  
Ionization Mass ◽  
Active Pharmaceutical Ingredients ◽  
Laser Desorption Ionization ◽  
Over The Counter ◽  
Pharmaceutical Ingredients ◽  
Desorption Ionization

Agglomeration of active pharmaceutical ingredients (API) in tablets can lead to decreased bioavailability in some enabling formulations. In a previous study, we determined that crystalline APIs can be detected as agglomeration in tablets formulated with amorphous acetaminophen tablets. Multiple method advancements are presented to better resolve agglomeration caused by crystallinity in standard tablets. In this study, we also evaluate three “budget” over-the-counter headache medications (subsequently labeled as brands A, B, and C) for agglomeration of the three APIs in the formulation: Acetaminophen, aspirin, and caffeine. Electrospray laser desorption ionization mass spectrometry imaging (ELDI-MSI) was used to diagnose agglomeration in the tablets by creating molecular images and observing the spatial distributions of the APIs. Brand A had virtually no agglomeration or clustering of the active ingredients. Brand B had extensive clustering of aspirin and caffeine, but acetaminophen was observed in near equal abundance across the tablet. Brand C also had extensive clustering of aspirin and caffeine, and minor clustering of acetaminophen. These results show that agglomeration with active ingredients in over-the-counter tablets can be simultaneously detected using ELDI-MS imaging.

scholarly journals Sulfanyl Porphyrazines with Morpholinylethyl Periphery—Synthesis, Electrochemistry, and Photocatalytic Studies after Deposition on Titanium(IV) Oxide P25 Nanoparticles

Molecules ◽  
2021 ◽  
Vol 26 (8) ◽  
pp. 2280
Author(s):  
Tomasz Koczorowski ◽  
Wojciech Szczolko ◽  
Anna Teubert ◽  
Tomasz Goslinski
Keyword(s):  
Diclofenac Sodium ◽  
2D Nmr ◽  
Oxide Nanoparticles ◽  
Electrochemical Studies ◽  
Macrocyclic Compounds ◽  
Active Pharmaceutical Ingredients ◽  
Pharmaceutical Ingredients ◽  
Vis Spectroscopy ◽  
Singlet Oxygen Quencher ◽  
Nmr Techniques

The syntheses, spectral UV–Vis, NMR, and electrochemical as well as photocatalytic properties of novel magnesium(II) and zinc(II) symmetrical sulfanyl porphyrazines with 2-(morpholin-4-yl)ethylsulfanyl peripheral substituents are presented. Both porphyrazine derivatives were synthesized in cyclotetramerization reactions and subsequently embedded on the surface of commercially available P25 titanium(IV) oxide nanoparticles. The obtained macrocyclic compounds were broadly characterized by ESI MS spectrometry, 1D and 2D NMR techniques, UV–Vis spectroscopy, and subjected to electrochemical studies. Both hybrid materials, consisting of porphyrazine derivatives embedded on the titanium(IV) oxide nanoparticles’ surface, were characterized in terms of particle size and distribution. Next, they were subjected to photocatalytic studies with 1,3-diphenylisobenzofuran, a known singlet oxygen quencher. The applicability of the obtained hybrid material consisting of titanium(IV) oxide P25 nanoparticles and magnesium(II) porphyrazine derivative was assessed in photocatalytic studies with selected active pharmaceutical ingredients, such as diclofenac sodium salt and ibuprofen.

US trade policy is putting at risk the sustainability of the generic/biosimilar industry and the drug supply chain

2021 ◽  
pp. 174113432199431
Author(s):  
María Fabiana Jorge
Keyword(s):  
Supply Chain ◽  
Trade Policy ◽  
Pharmaceutical Products ◽  
Drug Supply ◽  
Active Pharmaceutical Ingredients ◽  
Pharmaceutical Ingredients ◽  
Us Trade Policy ◽  
Drug Supply Chain ◽  
Security Concern ◽  
The U.S

With the outbreak of the Coronavirus there is a new realization of the vulnerabilities of the U.S. drug supply chain. However, while such concerns may have been amplified by the pandemic, they preceded Covid-19 and were well documented before 2020. Indeed, in past years the U.S. Congress held several hearings addressing potential vulnerabilities in the U.S. drug supply chain, in part due to the increasing dependency on China as a dominant supplier of active pharmaceutical ingredients (APIs) and some finished pharmaceutical products. These vulnerabilities go well beyond health policy and constitute a national security concern. The article addresses how U.S. trade policy plays a significant role in shaping the pharmaceutical industry at home and abroad and is in part responsible for some of the current vulnerabilities of the U.S. drug supply chain.

Sign in / Sign up

Export Citation Format

Share Document